Navigation Links
Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/3/2011

EAST BRUNSWICK, N.J., Nov. 3, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA® (pegloticase). Savient ended the quarter with $202.7 million in cash and short-term investments, a decrease of $37.6 million for the quarter.  For the third quarter of 2011, the Company had a net loss of $27.4 million, or $0.39 per share, on total revenues of $2.6 million, compared with a net loss of $59.4 million, or $0.89 per share, on total revenues of $1.0 million for the same period in 2010.  The net loss for the first nine months of 2011 was $71.2 million, or $1.02 per share, on total revenues of $5.9 million, compared with a net loss of $72.7 million, or $1.09 per share, on total revenues of $3.1 million for the same period in 2010.

"As pioneers in the refractory chronic gout market, we have spent the last several quarters building the foundation to support the commercialization of this one-of-a-kind treatment," said John H. Johnson, Chief Executive Officer and President.  "Through the validation of the importance of our Phase III clinical data published in JAMA and our expanding education programs, we are increasing awareness and understanding of KRYSTEXXA and beginning to change the lives of patients suffering from refractory chronic gout."

Operational Highlights:

  • Data from two pivotal KRYSTEXXA (pegloticase) Phase III clinical trials in patients with refractory chronic gout (RCG) were published in The Journal of the American Medical Association.  The  data published demonstrated that treatment with KRYSTEXXA resulted in significant and sustained reductions in uric acid levels along with clinical improvements in a substantial proportion of RCG patients
    '/>"/>

  • SOURCE Savient Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
    2. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
    3. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
    4. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
    5. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
    6. Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
    7. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
    8. Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA® Accepted for Review by European Medicines Agency
    9. Savient Pharmaceuticals Reports First Quarter 2011 Financial Results
    10. Savient Pharmaceuticals Submits European Marketing Authorization Application for KRYSTEXXA®
    11. Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/27/2015)... MARLBOROUGH, Mass. , Feb. 27, 2015  Boston ... to participate in the Barclays 2015 Annual Healthcare Conference ... . Dan Brennan , executive vice ... , vice president, Investor Relations, will participate in a ... the host analyst at approximately 1:05 p.m. ET. Following ...
    (Date:2/27/2015)... /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: ... results for its first quarter ended December 31, 2014. ... 31, 2014, revenue was $1,336,685. Operating expenses were $1,063,393. ... per share.  Covalon,s President and CEO, ... with the significant progress we have made over the ...
    (Date:2/27/2015)... -- Uroplasty, Inc. (NASDAQ: UPI ), a medical device ... to treat voiding dysfunctions, today announced that it will ... March 10, 2015. Rob Kill , President and ... will present at 4:00 p.m. Pacific Time and meet ... the Ritz Carlton in Laguna Niguel, CA. ...
    Breaking Medicine Technology:Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Uroplasty to Participate in the 27th Annual ROTH Conference 2
    ... , ... ... ... ...
    ... , ... ... ... ...
    Cached Medicine Technology:Frost & Sullivan Recognizes Timoptic(R) (timolol maleate) as Best Brand Name Beta Blocker for Glaucoma: Timoptic Brand is Highest Rated in Survey of Ophthalmologists 2Frost & Sullivan Recognizes Timoptic(R) (timolol maleate) as Best Brand Name Beta Blocker for Glaucoma: Timoptic Brand is Highest Rated in Survey of Ophthalmologists 3Frost & Sullivan Recognizes Timoptic(R) (timolol maleate) as Best Brand Name Beta Blocker for Glaucoma: Timoptic Brand is Highest Rated in Survey of Ophthalmologists 4Frost & Sullivan Recognizes Timoptic(R) (timolol maleate) as Best Brand Name Beta Blocker for Glaucoma: Timoptic Brand is Highest Rated in Survey of Ophthalmologists 5Frost & Sullivan Recognizes Timoptic(R) (timolol maleate) as Best Brand Name Beta Blocker for Glaucoma: Timoptic Brand is Highest Rated in Survey of Ophthalmologists 6STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 2STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 3STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 4STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 5STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 6STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 7STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 8STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 9STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 10STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 11STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 12STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 13STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 14STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 15STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 16STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 17
    (Date:2/28/2015)... 28, 2015 March—also known as ... to remind ourselves and others that suspected head ... NeuroSurgical Specialists (ANS). , Concussions are a form ... 75% of TBIs. There are 1.6-3.8 million sports-related ... benign, but it is a brain injury. Many ...
    (Date:2/28/2015)... Vancouver personal injury lawyers at Jiwa Law Corporation recently announced ... They stated that in many cases, missing an important time ... Many a time, delays in making an injury claim can ... As a result, experts at Jiwa Law Corporation suggest that ... injury lawyer in order to know more about their rights. ...
    (Date:2/28/2015)... A study out of the University of Oxford ... the treatment of a hereditary ocular condition that leads ... Dr. Robert MacLaren, professor of ophthalmology at the University ... on January 16, 2014 , the study treated six ... mostly affects men and leads to the degeneration of ...
    (Date:2/28/2015)... 28, 2015 The Mesothelioma Applied ... awards at the International Symposium on Malignant Mesothelioma on ... at the Hyatt Regency Bethesda in Bethesda, Maryland. The ... work and commitment to the mission to cure mesothelioma. ... will be presented to Miriam Ratner. Miriam runs the ...
    (Date:2/28/2015)... February 28, 2015 National ... outsourced sales, marketing and supply chain management for ... Botanicals, is bringing its award winning solutions for ... Botanicals’ products are specifically created to combat thinning-damaged ... BIOTA is committed to marrying science with nature ...
    Breaking Medicine News(10 mins):Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3
    ... sexually explicit, nude, or semi-nude photos by cell phone ... and teens. A new poll shows that the vast majority ... sext. Seventeen states have already enacted laws to address ... 2012 that focuses on sexting. The University ...
    ... 20 (HealthDay News) -- Seeing a baby,s face triggers a ... and planning movement, a finding researchers say may indicate a ... observed this pattern in adults who didn,t know the baby ... adults have no children of their own. Yet images of ...
    ... of scientific sessions will be devoted to the latest ... Heart Failure Congress 2012. The latest results from drugs ... Devices are one of the hottest topics in ... year,s main theme, "Treatment of heart failure: integrating pharmacology ...
    ... 20 (HealthDay News) -- The anti-inflammatory and painkiller ibuprofen ... to a new study. Headache, fatigue, nausea, dizziness, ... altitude sickness, which affects more than 25 percent of ... ski, hike or camp. If unrecognized or untreated, ...
    ... internal medicine physicians, or internists, subspecialists, medical students, and ... Internal Medicine 2012, the annual scientific meeting of the ... (Thursday - Saturday), at the Ernest N. Morial Convention ... of illnesses in adults. Internal Medicine 2012 is ...
    ... for early-career researchers in Germany have been announced. The ... Research Foundation) and the German Federal Ministry of Education ... three young women to receive the Heinz Maier-Leibnitz Prize ... Gebauer, Chemistry, University of Constance, Dr. Lisa Kaltenegger, Physics, ...
    Cached Medicine News:Health News:For youth sexting: Public supports education, not criminal charges 2Health News:Infants' Faces Trigger Caregiving Impulse in Adults' Brains 2Health News:The world's largest heart failure congress -- Heart Failure Congress 2012 2Health News:The world's largest heart failure congress -- Heart Failure Congress 2012 3Health News:Ibuprofen May Ward Off Altitude Sickness 2Health News:From diabetes to disaster relief: Story opportunities at Internal Medicine 2012 in New Orleans 2Health News:DFG announces recipients of 2012 Heinz Maier-Leibnitz Prize 2Health News:DFG announces recipients of 2012 Heinz Maier-Leibnitz Prize 3Health News:DFG announces recipients of 2012 Heinz Maier-Leibnitz Prize 4Health News:DFG announces recipients of 2012 Heinz Maier-Leibnitz Prize 5
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: